Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 01:35:05 14/05/26 am AEST			5-day change	1st Jan Change
13,766.00 ^GBX	+0.13%		+1.47%	-0.17%

13/05	ASTRAZENECA : Jefferies remains its Buy rating	ZD
13/05	AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making	MT

Press Releases

12/05	AstraZeneca : Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial	PU
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
07/05	AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026	AQ
04/05	AstraZeneca invests £300 million in UK drug development sites	AQ
01/05	TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
01/05	AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
01/05	AstraZeneca : Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer	PU
30/04	Astrazeneca injects £300m into UK sites	AQ
30/04	Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca	PR
29/04	Astrazeneca tops expectations in the first quarter on strong cancer drug sales	AQ
29/04	AstraZeneca results: Q1 2026	BU
29/04	AstraZeneca : Q1 2026 results clinical trials appendix (Q1 2026 results clinical trials appendix)	PU
29/04	Astrazeneca: Q1 Earnings Snapshot	AQ
28/04	BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older	BU
27/04	SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus	BU
20/04	Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD	BU
20/04	AstraZeneca : Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD	PU
10/04	AstraZeneca : Special Business Approved at AGM	PU
10/04	AstraZeneca : Results of Annual General Meeting held on 9 April 2026 (Results of Annual General Meeting held on 9 April 2026)	PU
09/04	AstraZeneca : Sustainability Data Reporting Criteria 2025	PU
09/04	AstraZeneca : Assurance Report for Sustainability Data Annex 2025	PU
09/04	AstraZeneca : Sustainability Data Annex 2025	PU
02/04	IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer	BU